Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
Tecentriq beats rivals to EU breast cancer marketRoche has claimed approval in Europe for Tecentriq as a therapy for hard-to-treat triple-negative breast cancer (TNBC), ahead Share XTecentriq beats rivals to EU breast cancer markethttps://pharmaphorum.com/news/tecentriq-beats-rivals-to-eu-breast-cancer-market/
Roche scores with Tecentriq combo in first-line bladder cancerRoche’s Tecentriq has become the first checkpoint inhibitor to show a benefit in previously-untreated patients with bladder cancer Share XRoche scores with Tecentriq combo in first-line bladder cancerhttps://pharmaphorum.com/news/roche-scores-with-tecentriq-combo-in-first-line-bladder-cancer/
Roche raises 2019 outlook, shrugging off biosimilar threatNew product sales helped Roche to a healthy 9% increase in sales in the first half of the Share XRoche raises 2019 outlook, shrugging off biosimilar threathttps://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/
Roche closes on EU approval for Tecentriq in breast cancerRoche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of Share XRoche closes on EU approval for Tecentriq in breast cancerhttps://pharmaphorum.com/news/roche-closes-on-eu-approval-for-tecentriq-in-breast-cancer/
Roche’s Tecentriq gains new US lung cancer indicationRoche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it Share XRoche’s Tecentriq gains new US lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gains-new-us-lung-cancer-indication/
Roche gets first checkpoint inhibitor OK in breast cancerRoche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to Share XRoche gets first checkpoint inhibitor OK in breast cancerhttps://pharmaphorum.com/news/roche-gets-first-checkpoint-inhibitor-ok-in-breast-cancer/
Roche pulls extended use application for kidney cancer drugRoche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy Share XRoche pulls extended use application for kidney cancer drughttps://pharmaphorum.com/news/roche-pulls-extended-use-application-for-kidney-cancer-drug/
Roche’s Tecentriq + Avastin racks up another combination successRoche has produced new data showing a combination of Tecentriq and older drug Avastin is more effective than Share XRoche’s Tecentriq + Avastin racks up another combination successhttps://pharmaphorum.com/news/tecentriq-avastin-combination-success/
